Oxford BioMedica Company Profile

13:04 EST 16th January 2019 | BioPortfolio

Oxford BioMedica advanced gene therapy techniques.


Robert Robertson AvenueThe Oxford Science Park
OX4 4 GA
United Kingdom


Phone: +44 1865 783 000
Fax: +44 1865 783 001

News Articles [308 Associated News Articles listed on BioPortfolio]

Oxford BioMedica Notes the Longer-Term Analyses from Pivotal Kymriah Trials, Which Showed Durable Responses Are Maintained in Patients with Advanced Blood Cancers

Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis on the longer-term analyses of both the ELIANA an...

Boehringer, Oxford BioMedica join on CF gene therapy project

Securing Oxford BioMedica's participation is indicative of the manufacturing hurdles present in gene therapy, particularly involving lentiviral vectors. 

Oxford BioMedica unveils digital initiative to streamline manufacturing

UK gene and cell therapy group Oxford BioMedica has announced a new digital framework initiative to streamline the production of next-generation medicines.

Boehringer secures option for cystic fibrosis gene therapy from Oxford BioMedica

Boehringer Ingelheim GMBH is expanding its reach into gene therapy via an option agreement with Oxford BioMedica PLC and Imperial Innovations Group PLC (tech transfer office of Imperial College of Lon...

Oxford Biomedica to expand with fourth site, creating 100 jobs

Gene and cell therapy group Oxford Biomedica has announced plans to expand its business with a new site located not far from its headquarters based in its namesake city of Oxford, UK. The new location...

Oxford BioMedica forms three-way partnership for cystic fibrosis treatment

Cystic fibrosis (CF) is characterized by abnormal ion transport in the apical membrane of epithelial cells. The partnership will use a novel and replication deficient lentiviral vector in The post Ox...

Oxford BioMedica (OXB) - Diversified strategy showing its strength

Edison Investment Research - Pharmaceutical & healthcare - Oxford BioMedica: Strong operational momentum at Oxford BioMedica (OXB), as evidenced by its interim maiden operating profit of £9.4m (...

Two huge licensing deals help Oxford BioMedica swing to a first-half profit

Oxford signed deals with Bioverativ and Axovant which could be worth upwards of US$1bn over the next few years

Drugs and Medications [0 Results]


PubMed Articles [636 Associated PubMed Articles listed on BioPortfolio]

Leishmaniasis cutánea y embarazo.

El drama de las enfermedades tropicales desatendidas.

Economía de la salud y salud pública: situación global y perspectivas locales.

Cross-cultural adaptation and validation of the Romanian Oxford Shoulder Score.

The use of validated patient reported outcome scores is critical to the reporting and monitoring of the effectiveness of clinical treatment. The aim of this study was to translate and culturally valid...

BulkVis: a graphical viewer for Oxford nanopore bulk FAST5 files.

The Oxford Nanopore Technologies (ONT) MinION is used for sequencing a wide variety of sample types with diverse methods of sample extraction. Nanopore sequencers output FAST5 files containing signal ...

Clinical Trials [101 Associated Clinical Trials listed on BioPortfolio]

Oxford Partial Knee Replacement. A Randomized Clinical Trial of Three Implant Types

The purpose of this scientific study is to clarify whether there is a relationship between the appearance of radiolucent lines in bone-cement interphase of the tibial component of the diff...

Comparison of Oxford UKA and Sigma UKA With RSA.

Comparison of two unicompartmental knee arthroplasties (UKA), to see if Sigma UKA performs equally good as the Oxford UKA. The study focuses on how well the arthroplasty is fixated to the ...

A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System

The purpose of this study is to collect information on complications and survivorship of patients implanted with the Oxford™ Meniscal Unicompartmental Knee System at multiple sites in th...

Oxford® Partial Knee Kinematics Gait Analysis Study

The objective of this study is to compare the effect on gait of unicompartmental knee arthroplasty (UKA), using the Oxford® Partial Knee, versus total knee arthroplasty (TKA), using the V...

Outcome Analysis of the Oxford Partial Knee Arthroplasty

Prospectively monitor the patients receiving the Oxford Partial knee arthroplasty

Companies [109 Associated Companies listed on BioPortfolio]

Oxford BioMedica

Oxford BioMedica advanced gene therapy techniques.

Oxford BioMedica plc

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the...

BioMedica Inc.

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was esta...

Boston Biomedica Incorporated

Boston Biomedica, Inc. is an infectious diseases management company providing products and services for the detection and treatment of infectious diseases (ID) such as AIDS, Lyme Disease, and Viral He...

Oxford Resource Partners, LP

Oxford Resource Partners, LP is a low cost producer of high value steam coal in Northern Appalachia and the Illinois Basin. Oxford markets its coal primarily to large electric utilities with coal-fir...

More Information about "Oxford BioMedica" on BioPortfolio

We have published hundreds of Oxford BioMedica news stories on BioPortfolio along with dozens of Oxford BioMedica Clinical Trials and PubMed Articles about Oxford BioMedica for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oxford BioMedica Companies in our database. You can also find out about relevant Oxford BioMedica Drugs and Medications on this site too.

Quick Search


Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Corporate Database Quicklinks

Searches Linking to this Company Record